Literature DB >> 17372026

Augmentation of NZB autoimmune phenotypes by the Sle1c murine lupus susceptibility interval.

Brendan M Giles1, Svetlana N Tchepeleva, Julie J Kachinski, Katherine Ruff, Byron P Croker, Laurence Morel, Susan A Boackle.   

Abstract

The Sle1c lupus susceptibility interval spans a 7-Mb region on distal murine chromosome 1. Cr2 is the strongest candidate gene for lupus susceptibility in this interval, as its protein products are structurally and functionally altered. B6.Sle1c congenic mice develop Abs to chromatin by 9 mo of age with a 30% penetrance and do not develop GN. To determine whether the New Zealand White (NZW)-derived Sle1c interval would interact with New Zealand Black (NZB) genes to result in enhanced autoimmune phenotypes, NZB mice were bred with B6 or B6.Sle1c congenic mice and approximately 20 female offspring were selected from each breeding for longitudinal study. These mice differ only at the Sle1c locus at which they have either a NZB/B6 or NZB/NZW genotype. NZB x B6.Sle1c mice had an accelerated onset of anti-chromatin Abs (100 vs 68% at 6 mo, p = 0.006) and anti-dsDNA Abs (45 vs 5% at 9 mo, p = 0.0048). Furthermore, median titers of anti-chromatin and anti-dsDNA Abs were significantly higher in the NZB x B6.Sle1c group compared with the NZB x B6 group. This corresponded with a higher prevalence of proliferative GN at 12 mo (55 vs 16%, p = 0.0214) as well as increased glomerular deposition of C3 (p = 0.0272) and IgG (p = 0.032), although blood urea nitrogen remained normal and significant proteinuria was not identified in either group. These data show that the Sle1c interval accelerates and augments the loss of tolerance to chromatin and dsDNA induced by NZB genes and induces significantly greater end-organ damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372026     DOI: 10.4049/jimmunol.178.7.4667

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  IgG autoantibodies against deposited C3 inhibit macrophage-mediated apoptotic cell engulfment in systemic autoimmunity.

Authors:  Karla D Kenyon; Caroline Cole; Fran Crawford; John W Kappler; Joshua M Thurman; Donna L Bratton; Susan A Boackle; Peter M Henson
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

Review 2.  Macrophages and immunologic inflammation of the kidney.

Authors:  Jeremy S Duffield
Journal:  Semin Nephrol       Date:  2010-05       Impact factor: 5.299

Review 3.  Genetic and hormonal factors in female-biased autoimmunity.

Authors:  Anatoly V Rubtsov; Kira Rubtsova; John W Kappler; Philippa Marrack
Journal:  Autoimmun Rev       Date:  2010-02-06       Impact factor: 9.754

4.  Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor γ.

Authors:  Daniel J Perry; Yiming Yin; Tiffany Telarico; Henry V Baker; Igor Dozmorov; Andras Perl; Laurence Morel
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

5.  Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1.

Authors:  Zhiwei Xu; Hari-Hara S K Potula; Anusha Vallurupalli; Daniel Perry; Henry Baker; Byron P Croker; Igor Dozmorov; Laurence Morel
Journal:  J Immunol       Date:  2011-05-04       Impact factor: 5.422

6.  Murine lupus susceptibility locus Sle1a requires the expression of two sub-loci to induce inflammatory T cells.

Authors:  C M Cuda; L Zeumer; E S Sobel; B P Croker; L Morel
Journal:  Genes Immun       Date:  2010-05-06       Impact factor: 2.676

Review 7.  Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus.

Authors:  Brendan M Giles; Susan A Boackle
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

8.  Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing.

Authors:  K B Douglas; D C Windels; J Zhao; A V Gadeliya; H Wu; K M Kaufman; J B Harley; J Merrill; R P Kimberly; G S Alarcón; E E Brown; J C Edberg; R Ramsey-Goldman; M Petri; J D Reveille; L M Vilá; P M Gaffney; J A James; K L Moser; M E Alarcón-Riquelme; T J Vyse; G S Gilkeson; C O Jacob; J T Ziegler; C D Langefeld; D Ulgiati; B P Tsao; S A Boackle
Journal:  Genes Immun       Date:  2009-04-23       Impact factor: 2.676

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.